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▪PhD research activities (starting in 2006) initially in 7 EU 
countries to:
❑ Increase the prescribing of generics first line and drive down 
their prices to enhance prescribing efficiency
❑ Optimise reimbursement/ funding decisions for new 
medicines and their subsequent utilisation leading to the 
development of new models starting pre-launch
▪Research interests subsequently extended globally and include 
activities to improve the quality and efficiency of prescribing/ 
dispensing of new and established medicines across multiple 
disease areas/ product classes including infectious and NCDs. This 
includes issues of drug shortages and potential ways to address 
this
▪Co-Founder of Piperska (Europe - 2008) and MURIA (2015)
▪Over 350 peer reviewed publications in the past 15 years with 
payers/ advisers/ academics across multiple continents/ countries 
including Asia – with most listed in Pub Med
Brian Godman – research activities
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▪We do know that patients have adverse economic, clinical and 
humanistic outcomes as a result of medicine shortages leading 
to activities to try address this including LMICs such as Africa  
▪The situation is exacerbated in Africa with the highest rates of 
both infectious diseases and non-infectious diseases globally 
but issues with pro-activity and payment for medicines
▪To date among hospitals in Africa there has only been a limited 
number of studies documenting drug utilisation patterns. In 
addition, concerns with the lack of medicine use policies/ 
activities including drug and therapeutic committees and 
antimicrobial stewardship programmes
▪Similarly studies regarding drug shortages and the 
implications going forward. However, this is changing 
▪We are also now seeing studies on the use of HFMEA 
approaches to proactively improve future care. Such activities 
can be used to address drug shortages – building on 
increasing local production post COVID-19
Drug shortages pose problems for all key 
stakeholders. HFMEA provides opportunities
Ref: Neff et al 2018; Acosta et al 2019; Garcia et al 2019; Modasakeng et al 2020; Ogunleye 2020
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We are seeing studies assess drug utilization patterns 
in hospitals including Kenya providing direction
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We are also seeing studies assessing antimicrobial usage 
patterns in hospitals including PPS studies, e.g. Botswana
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However – there are concerns with the lack of DTCs 
and ASPs among a number of African countries 
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However – there are concerns with the lack of DTCs 
and ASPs among a number of African countries 
EAHP 20208
There are also issues of drug shortages, e.g. South 
Africa, exacerbated by concerns with suppliers
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Potential ways forward include instigating therapeutic 
interchange programmes and proactive risk assessment
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Potential ways forward include instigating therapeutic 
exchange programmes and proactive risk assessment
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▪Medicine shortages are a key and growing issue across LMICs 
including Africa
▪Proactive risk assessment approaches are possible building on 
recent experiences across Europe and Kenya
▪However key issues include manpower (although hospital 
pharmacists currently spend a great deal of time trying to 
address shortages and agree potential therapeutic exchanges) 
and experience – colleagues in Europe can help here
▪The rise in DTCs and ASPs to address key issues regarding 
improving the appropriate use of medicines in hospitals 
especially antimicrobials will also help here – along with 
programmes such as instigating quality improvement 
programmes to assess current prescribing against agreed 
guidance  
▪Other ways forward to address drug shortages building on the 
recent experience with COVID-19 is to enhance local 
production facilities
Medicine shortages are a key issue across 
LMICs. Proactive approaches can help
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There are increasing studies to assess prescribing 
against current guidance aiding proactive approaches
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Any Questions!
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